Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

NCT07359820 is registered in ClinicalTrials.gov with Elevar Therapeutics as lead sponsor.

NCT NCT07359820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07359820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
Lead sponsor
Elevar Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
June 4, 2026
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

fgfr2 gene fusion/rearrangement, other solid tumors, adult